Nathanael L. Dirks, Pharm.D., Ph.D.

Principal Scientist II

Nathanael joined Metrum in 2010 after receiving his Pharm.D. and Ph.D. (Pharmaceutical Sciences). In his tenure at Metrum, Nathanael has applied both clinical pharmacy knowledge and pharmacometric methods to PK/PD modeling and simulation analyses and strategic decision making at all stages of drug development. His clinical experience spans a broad range of small molecule and biologic therapeutics in a number of therapeutic areas with particular emphasis in pediatric pharmacology, rare diseases, pain management, and inflammatory diseases.

Recent publications by this scientist

Population pharmacokinetic modeling of vedolizumab for graft-versus-host disease prophylaxis in adults with Allogeneic Hematopoietic Stem Cell Transplant.

September 5, 2024

This study characterizes the population pharmacokinetics (PK) of vedolizumab in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for graft-versus-host disease (GvHD) prophylaxis. The analysis identified body weight and albumin levels as significant predictors of vedolizumab clearance, though the covariates studied had no clinically meaningful effect on its overall PK. The findings offer important insights into dosing strategies for vedolizumab in this patient population.

Read Article

Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis

March 6, 2024

This posthoc analysis of the GEMINI and VISIBLE studies in ulcerative colitis (UC) and Crohn’s Disease (CD) assessed exposure−efficacy of vedolizumab intravenous (IV) and subcutaneous (SC).

Read Article

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease.

January 13, 2021

Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Intest Res. 2021;19(1):95-105. doi:10.5217/ir.2019.09167.